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Burkholderia cepacia complex (BCC) bacteria can cause devastating chronic infections in
people with cystic ﬁbrosis. Of particular concern is “cepacia syndrome,” a rapidly pro-
gressive and usually fatal decline in health, characterized by a necrotizing bacteremic
pneumonia. An important component of defense against bloodstream infections is the
bactericidal action of serum. Traditional methods to determine the capacity of bacterial
isolates to resist the bactericidal effects of serum are relatively low-throughput viability
assays. In this study, we developed a novel growth-based assay for serum susceptibility,
which allows for high throughput analysis. We applied this assay to a range of clinical iso-
lates of BCC as well as isolates comprising the BCC experimental strain panel. Our data
demonstrate that isolates from all species of BCC examined can possess serum resistant
or serum sensitive/intermediate phenotypes. Of particular clinical signiﬁcance, we also
found no direct link between the last saved pulmonary isolate from patients who subse-
quently developed “cepacia syndrome” and their capacity to resist the inhibitory effects
of human serum, suggesting serum resistance cannot be used as a marker of an isolate’s
capacity to escape from the lung and cause bacteremia.
Keywords: Burkholderia cepacia complex, serum, cystic fibrosis, complement, Bioscreen, cepacia syndrome
INTRODUCTION
Bacteria belonging to the Burkholderia cepacia complex (BCC)
can cause devastating pulmonary infections in people who have
cystic ﬁbrosis (CF). The BCC is composed of at least 17 distinct
species, all of which, except B. ubonensis, have been isolated from
the lungs of peoplewithCF (Mahenthiralingamet al., 2008). Infec-
tion with BCC bacteria can be a frightening prospect for people
with CF because these bacteria are known to cause devastating
clinical deterioration in a subset of patients, and it is not possi-
ble to determine a priori which are at risk. Individuals with BCC
respiratory infection can show either no substantive change in
pulmonary function, a gradual decline in health or, worst of all,
an invasive, and rapidly fatal septicemia known as “cepacia syn-
drome” (Isles et al., 1984; Glass and Govan, 1986). The reasons
for these disparate outcomes are not understood; thus accurate
prognoses for CF patients infected with BCC are extremely dif-
ﬁcult to deﬁne. While a number of different BCC species have
been associated with “cepacia syndrome” (Zahariadis et al., 2003;
Nash et al., 2011), historically infections caused by Burkholderia
cenocepacia have been associated with a higher risk of develop-
ing“cepacia syndrome” than the other species (Mahenthiralingam
et al., 2001; Jones et al., 2004). A further complication of infection
with B. cenocepacia appears to be a higher risk of death following
lung transplantation, often as a result of sepsis (Alexander et al.,
2008; De Soyza et al., 2010).
Serum-mediated bactericidal activity is an especially important
innate immune defense against intravascular invasion of bacter-
ial pathogens and is thought to occur as a result of membrane
attack complexes (MAC) that are assembled from terminal com-
plement components in the bacterial cell envelope (Frank et al.,
1987; Walport, 2001). Serum resistance of bacteria occurs as a
result of the failure of complement-mediated lysis. Most isolates
of Pseudomonas aeruginosa from chronically infected CF patients
are serum-susceptible; this is thought to explain in part why P.
aeruginosa bacteremia/septicemia is essentially never seen in CF
(Hoiby and Olling, 1977; Thomassen and Demko, 1981; Speert
et al., 1990). In the context of BCC, serum sensitivity/resistance
might be an important microbial phenotype, which could con-
ceivably differentiate between invasive and non-invasive strains
and isolates. This could be especially important in the context
of “cepacia syndrome,” where the invading strain would have to
be able to resist the effect of complement either through intrinsic
resistance to the formation of the MAC in the bacterial membrane,
or by interfering with the complement cascade that leads to the
formation of the MAC.
Serum sensitivity and serum resistance phenotypes have both
been described previously in BCC isolates from patients with CF;
the isolates studied had rough lipopolysaccharide (LPS) render-
ing them serum sensitive (Butler et al., 1994). The mechanistic
basis of serum resistance in BCC is not fully understood; how-
ever, consistent with the observations of Butler et al. possession
of a complete LPS has been shown to confer resistance to serum
(Ortega et al., 2005). Another type of polysaccharide – secreted
exopolysaccharides – may also be signiﬁcant in serum resistance
as a recent study on a small number of B. cenocepacia isolates
suggested that the “mucus layer”may also contribute to resistance
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to the bactericidal effects of serum (Savoia et al., 2008). Indeed,
BCC are capable of synthesizing at least ﬁve different exopolysac-
charides (Cescutti et al., 2010). In characterizing a pair of isogenic
clonal non-mucoid/mucoid clinical isolates, C8963 (non-mucoid)
and C9343 (mucoid), we noticed that the non-mucoid C8963 was
serum resistant in spite of its rough LPS, while the mucoid C9343
was serum sensitive (Conway et al., 2004). However, these stud-
ies were either performed before BCC had been reclassiﬁed into
species (Vandamme et al., 1997) or before mucoidy was recog-
nized as a common phenotypic feature of the complex (Cunha
et al., 2004; Zlosnik et al., 2008).
The purpose of this study was to develop a higher through-
put and automated technique for assessing the capacity of human
serum to inhibit the growth of BCC isolates in order to facilitate
an improved understanding of mechanisms of virulence in these
invasive CF pathogens. Additionally, we applied this technique to
determine the serum resistance phenotypes of a range of clinical
isolates and representative isolates comprising the BCC experi-
mental strain panel (Mahenthiralingam et al., 2000). These data
show that both serum resistant and serum sensitive/intermediate
phenotypes can be found in isolates of each of the ﬁve species
examined. Furthermore, we examined a range of clinical isolates
of BCC from patients who died from“cepacia syndrome”and were
unable to ﬁnd a link between the serum resistance phenotype of
the last saved pulmonary isolate and subsequent progression to
“cepacia syndrome”.
MATERIALS AND METHODS
SOURCE OF BACTERIAL ISOLATES AND HUMAN SERUM
Clinical isolates of BCC bacteria were taken from the Canadian
BCC research and referral repository (CBCCRRR; Speert et al.,
2002). Serum resistant (B. cenocepacia K56-2, and C8963 and P.
aeruginosa M2) and serum sensitive (B. cenocepacia J2315, C9343,
and P. aeruginosa P1) have been previously described (Dasgupta
et al., 1994; Conway et al., 2004; Ortega et al., 2005). Bacteria were
grown from cultures stored at −80˚C on to Columbia Blood Agar
plates for 24–48 h at 37˚C and plates were passaged no more than
three further times before reverting to the freezer stock. Com-
plement preserved pooled normal human serum (PNHS; Inno-
vative Research, MI, USA) was used in all experiments. For heat
inactivated serum assays, PNHS was heated to 65˚C for 30 min.
ASSESSMENT OF BACTERIAL VIABILITY AFTER TREATMENT WITH
SERUM
The viability of bacteria following treatment with serum was
determinedby amodiﬁcationof a previously described assay (Das-
gupta et al., 1994). Brieﬂy, isolates were grown overnight in LB
broth (10 g l−1 tryptone, 5 g l−1 yeast extract, and 10 g l−1 sodium
chloride) at 37˚C on an orbital rotator, then 1 ml of overnight
culture was pelleted at 3,000 rpm (800× g ) for 5 min in a Jouan
A14 microcentrifuge, resuspended in Hanks Balanced Salt Solu-
tion (GIBCO) with 0.1% gelatin and adjusted to 1× 108 colony
forming units (CFU) ml−1. 106 CFU were then transferred to a
5-ml polypropylene tube and incubated with 10% serum in a
ﬁnal volume of 3 ml for 180 min at 37˚C with tumbling. CFU
were determined at 0 and 180 min by serial dilution and culture;
serumsensitive isolatesweredeﬁnedby a≥90%reduction in viable
count between 0 and 180 min, while serum resistant isolates were
classiﬁed by <20% loss in viability. Between 20 and 90% loss in
viability was classiﬁed as indeterminate. For direct comparison
with the automated growth assessment, serum resistance was also
assessed using the above method, except using an inoculum of
1× 107 CFU ml−1, and with CFUs determined at 0 and 720 min.
All isolates were characterized in experiments on at least three
separate days.
AUTOMATED GROWTH ASSESSMENT OF SERUM SUSCEPTIBILITY
Overnight cultures were grown in LB broth and then pelleted
at 3,000 rpm (800× g ) for 10 min in a Juan A14 microcen-
trifuge. The cell pellets were resuspended in 1 ml LB broth and
adjusted to an OD600 nm of approximately 0.1 (equivalent to
1.0× 108 CFU/ml) using fresh LB broth. Thirty microliters of
the adjusted overnight culture was then inoculated into 270μl
of LB broth with 11% pooled human serum (resulting in a ﬁnal
inoculum of 107 CFU ml−1 in 10% serum) in a Bioscreen 100
well honeycomb plate. An equal number of control wells, without
serum, were set up for each isolate in all experiments performed,
as were blank wells containing only growth media (with or with-
out serum). Growth at 37˚C was then monitored in a Bioscreen C
machine (TYPEFP-1100-C,OyGrowthCurvesAbLtd.)withmea-
surement intervals of 15 min and continuous shaking at medium
amplitude, controlled by EZ experiment software.
DATA PROCESSING
Growth of all isolates was assessed at each time point by subtract-
ing the value for the media blank from the mean OD600 nm of
experimental replicates. The serum resistance phenotype for each
isolate was then determined by calculating the average percent
increase in OD in the wells containing serum compared to wells
without serum at 12 h. For the growth-based assay, serum sensitive
isolates were considered to be those that had failed to reach 20%
growth in PNHS at 12 h compared to no-serum controls. Serum
resistant isolates were deﬁned as those that reached 80% or more
growth in PNHS at 12 h compared to no-serum controls, while
those isolates that grew between 20 and 80% in PNHS compared
to no-serum controls were considered intermediate. For each iso-
late, replicates were performed on at least three different days. All
data were processed in MS Excel.
RESULTS
AUTOMATED GROWTH ANALYSIS TO ASSESS SERUM RESISTANCE
The traditional method to determine serum resistance of bacterial
isolates is to expose them to human serum, in a medium that does
not support growth, for several hours, and then measure viable
counts to assess whether or not an isolate is susceptible or resistant
(Butler et al., 1994; Ortega et al., 2005). However, although effec-
tive and direct, manual counts of viability are laborious and time
consuming. Therefore, we sought to evaluate alternative meth-
ods. Initially, we assessed both a Live/Dead BacLight™(Molecular
Probes) kit assay, based on staining of live and dead cells, and the
BacTiter-Glo™(Promega) cell viability assay based on the detec-
tion of ATP as an indicator of cell viability. Neither technique
proved suitable for our needs to assess serum resistance, due to
interference by components of human serum or cost of reagents
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(data not shown). Therefore, we investigated whether or not the
inhibitory effects of human serum could be determined using an
automated growth curve machine, reasoning that serum sensitive
isolates would not growor display inhibited growth in the presence
of serum.
Using a Bioscreen automated growth curve machine we eval-
uated control isolates, with known serum resistance phenotypes,
of both B. cenocepacia (Figure 1) and P. aeruginosa (data not
shown). Under standard growth conditions, we found that 10%
serum inhibited the growth of serum sensitive isolates (B. ceno-
cepacia J2315 and P. aeruginosa P1) in a highly reproducible
manner, while serum resistant (B. cenocepacia K56-2 and P. aerug-
inosa M2) isolates grew normally (Figure 1, P. aeruginosa isolates
data not shown). Other studies report a range of different serum
concentrations (between 5 and 40%) to assess serum susceptibil-
ity (Hancock et al., 1983; Butler et al., 1994; Ortega et al., 2005;
Savoia et al., 2008). Therefore, we investigated the growth of the
three control serum resistant isolates in 10, 20, and 40% pooled
normal human serum (PNHS). We found that P. aeruginosa M2
isolate grew normally at all concentrations, while serum resistant
B. cenocepacia K56-2 grew normally at both 10 and 20% serumbut
exhibited delayed growth in 40% serum (data not shown). Finally,
C8963 grew normally at 10% serum, exhibited delayed growth
at 20% serum and did not grow at all in 40% serum (data not
shown). We elected to use 10% serum in all further experiments
as all previously described serum resistant isolates grew normally
at this concentration.
In order to create a quantitativemeasure of the extent of growth
inhibition by serum, we normalized all data generated by the
Bioscreen C machine, calculating the mean percentage growth of
an isolate in serum compared to the mean growth of the isolate in
an equal number of control wells containing the same media with-
out serum (Figure 2). An isolate’s serum resistance phenotype was
then determined by the percentage growth in PNHS compared to
growth in media alone at 12 h. This time point was chosen to allow
the control wells to have grown into stationary phase as well as to
reduce some of the “noise” generated by the less accurate read-
ings taken at the time of initial inoculum. Serum resistant isolates
were characterized as achieving 80% or greater of the OD600 nm of
the no-serum control wells at 12 h. Serum sensitive isolates were
deﬁned as measuring less than 20% of the OD increase of the no-
serum control wells. Isolates that achieved between 20 and 80% of
the OD of the no-serum control wells were classiﬁed as intermedi-
ate. It was notable that the sensitive control isolate P. aeruginosa P1
demonstrates regrowth at 24 h (Figure 2). To assess the prevalence
of this phenomenon, we examined a larger range of BCC isolates
(Table 1). We found that all isolates classiﬁed as intermediate had
fully grown at 24 h. Of the strains classiﬁed as sensitive, 4/9 (BCC
isolates C7376, C8482, and C4365 as well as P. aeruginosa P1)
demonstrated growth recovery (to either intermediate or resistant
phenotype) at 24 h, while 5/9 (J2315. C9343, C2864, C4380, and
C4873) remained classiﬁed as sensitive (Table 1).
To validate the Bioscreen automated growth curve method for
assessing serum resistance we conducted a number of additional
experiments. Firstly, to ensure that the growth inhibition of serum
sensitive isolates was due to the heat-labile fraction of PNHS, we
grew the three control serum sensitive isolates in heat inactivated
serum. In all cases, heat inactivation rendered PNHS incapable of
FIGURE 1 | Growth of B. cenocepacia isolates in LB with (solid shapes) and without (open shapes) 10% pooled normal human serum in a Bioscreen
growth curve machine. Squares=B. cenocepacia K56-2 (serum resistant) and triangles=B. cenocepacia J2315 (serum sensitive). All experiments were
performed in triplicate with three biological repeats, error bars are standard errors of the mean and where not visible are smaller than the symbols.
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FIGURE 2 | Percentage growth of isolates in LB supplemented with 10%
pooled normal human serum in a Bioscreen growth curve machine
compared to no-serum controls grown in LB. Squares=B. cenocepacia
K56-2 (serum resistant), crosses=P. aeruginosa M2 (serum resistant),
diamonds=P. aeruginosa P1 (serum sensitive), and triangles=B.
cenocepacia J2315 (serum sensitive). All experiments were performed in
triplicate with three biological repeats, error bars are standard errors of the
mean where not visible are smaller than the symbols.
inhibiting bacterial growth (Figure 3). Secondly, to demonstrate
that the Bioscreen generates equivalent data to the conventional
serum assay, we determined the serum killing in the conventional
assay at 12 h for the control isolates used in this study. These data
(Table 1) showed, with the exception of C8963, agreement with
the Bioscreen method. Additionally, it is notable that these data
also show that serum resistant isolates of P. aeruginosa (M2) andB.
cenocepacia (K56-2,C3921,C3921-CTZ32G) grow in the presence
of serum over the course of 12 h with all gaining at least a one log
increase in CFU, suggesting they are growing on nutrients present
in the serum. Finally, data from the Bioscreen automated growth
curve method also showed good concordance with measurements
of viability performed using the traditional serum sensitivity assay
at 3 h with 75% (±20 at a 95% conﬁdence interval of the mean)
isolates giving identical results (Table 1).
APPLICATION OF THE BIOSCREEN METHOD TO A RANGE OF BCC
BACTERIA
To demonstrate the utility of the Bioscreen assay, we applied this
technique to characterize the isolates comprising the BCC strain
panel (Mahenthiralingam et al., 2000). This panel contains rep-
resentative isolates for the species B. cepacia, B. multivorans, B.
cenocepacia, B. stabilis, and B. vietnamiensis. These data identify
serum resistant and sensitive isolates in all species except for B.
cepacia, where only resistant and intermediate phenotypes were
found in the four isolates representing that species (Table 2).
We have previously shown that a non-mucoid clinical isolate
of B. cenocepacia (C8963) is serum resistant, while a mucoid
sequential clonal isolate from the same infection (C9343) was
serum sensitive. This observation was repeated in both methods
used in this study (Table 1). In this study, we also examined a non-
mucoid isolate that we have previously derived from a mucoid
parent under antibiotic pressure (Zlosnik et al., 2011). This iso-
late, C3921-CTZ32G, and its parent, C3921, both displayed serum
resistance and therefore the absence of exopolysaccharide produc-
tion capacity is not linked to the serum resistance phenotype in
these isolates (Table 1). Additionally, both serum resistant and
serum sensitive/intermediate phenotypes were found for mucoid
and non-mucoid isolates of B. cenocepacia (Tables 1 and 3). We
also examined the serum resistance phenotypes of further B. ceno-
cepacia clinical isolates in order to have assessed a range of exam-
ples of themajor epidemic clones ofB. cenocepacia (Table 3). These
data also suggest that there is no direct link between serum resis-
tance and RAPD type; sensitive/intermediate and resistant isolates
were found for all RAPD types examined (Tables 1 and 3).
“Cepacia syndrome” is a necrotizing pneumonia, often involv-
ing a fatal bloodstream invasion from the pulmonary tract by the
infecting BCC bacterium, and currently there are no known pre-
dictive factors, either microbial or human, of this phenomenon.
We reasoned that to result in bloodstream invasion, a BCC iso-
late would need to be serum resistant. Therefore, we constructed
a hypothesis that the last stored pulmonary isolate taken from
patients that subsequently develop “cepacia syndrome” would be
serum resistant to facilitate intravascular invasion. Should this
prove to be the case, it could be used as a risk factor for “cepa-
cia syndrome”. To investigate this hypothesis we retrieved the last
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FIGURE 3 | Bioscreen growth curves of serum sensitive isolates in
10% pooled normal human serum (open shapes) and heat inactivated
pooled normal human serum (HIS, solid shapes). Diamonds=P.
aeruginosa P1, triangles=B. cenocepacia J2315, and circles=B.
cenocepacia C9343. All experiments were performed in triplicate with
three biological repeats. Error bars are standard errors of the mean, where
not visible are smaller than the symbols and only the upper error bars are
included for clarity.
storedpulmonary isolate fromninepatients thatwere annotated in
our database as having subsequently developed cepacia syndrome
or severe pneumonia that led to death (Mahenthiralingam et al.,
2001; Zlosnik et al., 2011) and assessed their resistance to serum
using both a traditional serum sensitivity assay and our Bioscreen
growth-based assay (Table 1). From the nine cases of cepacia syn-
drome that were analyzed, we found that the last stored isolate
was resistant to serum in two cases, susceptible in three cases,
and of intermediate resistance in four cases. In one case, BCC5,
there were two isolates stored on the same day prior to death and
it was notable that these displayed different serum resistance pro-
ﬁles withC4871 being serum intermediate andC4872 being serum
resistant.
DISCUSSION
The capacity to resist the bactericidal effects of human serum is
thought to be an important adaptation in a number of bacteria
capable of causing septicemia, such as Neisseria meningitidis, in
otherwise healthy people (Kugelberg et al., 2008; Lambris et al.,
2008). Complement activity represents one of the primary lines
of defense of the human body against systemic bacterial infec-
tion. Indeed, defects in components of the complement cascade
are associated with an elevated susceptibility to serious infections
caused by a number of bacteria, including Haemophilus inﬂuenzae
and Streptococcus pneumoniae (Walport, 2001).
Assessing serum resistance in bacterial isolates is a time con-
suming and low-throughput process involving enumerating CFU
before and after exposure to serum in a medium that does not
support growth of the bacterium. A number of modiﬁcations and
alternatives have been described (Provonchee and Zinner, 1974;
Hancock et al., 1983;Pelkonen,1987),but the assays remaindepen-
dent upon enumeration of viable bacteria. This study presents a
further reﬁnement, demonstrating the applicability of a growth-
based method for assessing serum resistance in bacteria that allows
for larger numbers of isolates to be assessed at one time. Con-
ceptually, this method differs from others in that it assesses the
ability of an isolate to grow in a medium that supports bacterial
growth rather than a direct assessment of bacterial killing. This
could have a number of advantages; ﬁrstly, by using an automated
growth machine this method allows for a higher throughput of
isolates. Secondly, unlike the traditional serum sensitivity assay,
which determines killing of bacteria, a growth-based assay assesses
whether or not resistant bacteria have the capacity to continue to
thrive in the presence of serum. The Bioscreen automated growth
assay proved to be an effective alternative method to assess the
capacity of serum to inhibit B. cenocepacia isolates by determining
the percentage inhibition of growth at 12 h (Figure 2). In con-
trast, traditional methods involve serial dilution and plating both
before and after exposure to serum,which for even a small number
of isolates is a process that is highly time consuming and laborious,
requiring a minimum of 24 h (usually 48 h for the slower grow-
ing BCC). Furthermore, the Bioscreen automated growth assay
provided data consistent with those from the traditional serum
sensitivity test (Table 1).
The Bioscreen machine has been successfully used as a higher-
throughput method to assess the inhibitory proﬁle of a number of
different antimicrobial compounds including antibiotics (Löwdin
et al., 1998), disinfectants (Lambert et al., 1998), and biocides
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Table 2 | Bioscreen determined serum susceptibility profiles of
representative isolates of BCC.
Species Isolate % Growth
at 12h (SEM)
Serum
phenotype
B. multivorans C5393 82.5 (0.71) R
LMG13010T 96.1 (1.02) R
C1576 84.4 (1.58) R
CF-A1-1 −0.74 (0.87) S
JTC 87.1 (0.91) R
C1962 85.6 (6.82) R
ATCC17616 −0.51 (0.47) S
249-2 −1.26 (0.31) S
B. cenocepacia J2315 SeeTable 1 S
BC7 61.7 (11.7) I
K56-2 SeeTable 1 R
C5424 108 (4.15) R
C6433 82.4 (2.5) R
C1394 1.33 (1.33) S
PC184 −0.93 (1.24) S
CEP511 −1.31 (0.34) S
J415 121 (39.7) R
ATCC1765 69.1 (10.3) I
B. cepacia ATCC25416T 82.8 (2.76) R
ATCC17759 81.9 (1.45) R
CEP509 75.0 (1.81) I
LMG17997 61.6 (11.4) I
B. stabilis LMG14294 1.84 (4.55) S
C7322 ND ND
LMG14086 109 (11.8) R
LMG18888 27.7 (5.8) I
B. vietnamiensis PC259 −0.64 (0.51) S
LMG16232 89.5 (1.71) R
FC441 87.4 (1.41) R
LMG10929 123.7 (35) R
Serum resistance phenotypes were determined using the Bioscreen growth
method. R, resistant (>80% growth in serum); S, sensitive (<20% growth
in serum); and I, intermediate (20–80% growth in serum) at 12 h. ND, not
determined. Experiments were performed in triplicate on three separate days.
(Lambert et al., 1998) as well as to assess the bacteriolytic effect of
bacteriophages (Cooper et al., 2011). In addition to throughput of
isolate numbers and decreased time to result, one further advan-
tage that the Bioscreen assay offered over the traditional serum
resistance was the ability to monitor the dynamics of growth in
the presence of serum. Speciﬁcally, we were able to show that
all isolates classiﬁed as intermediate, and a number classiﬁed as
serum sensitive, eventually do grow in the presence of serum
(Table 1). This observation is similar to the recent study that uti-
lized theBioscreenmachine to assess bacteriophage activity against
P. aeruginosa, here the authors found the Bioscreen machine to be
more stringent and that it identiﬁed the regrowth of someP. aerug-
inosa samples 20 h after treatment with bacteriophage (Cooper
et al., 2011). Such observations may have biological signiﬁcance
in vivo. Finally, while we used a Bioscreen machine in this study,
because it permits a full characterization of the growth of isolates
Table 3 | Serum susceptibility phenotypes of additional
B. cenocepacia clinical isolates.
Isolate RAPD type % Growth
at 12h (±SEM)
Serum resistance
phenotype
EPS
C0131 04 98.7 (2.3) R ++
C1257 01 26.4 (5.7) I +++
C2303 06 1.9 (2.0) S ++
C2457 06 3.53 (2.8) S +++
C3883 04 93.7 (3.3) R +++
C4526 04 70.7 (26.4) I +++
C5491 01 40.2 (16.0) I −
C5819 04 177.3 (19.8) R ++
C6114 04 107.9 (42.0) R +++
C6144 06 0.7 (0.5) S −
C6159 073a 89.4 (6.3) R ++
C6345 02 8.8 (4.9) S −
C6483 02 99.4 (10.9) R −
C6615 X 86.7 (5.6) R −
C7586 04 149.5 (3.7) R +++d
C7755 067 90.5 (1.8) R +++d
C7788 04 104.3 (29.7) R −
D0134 X 123.6 (17.3) R +++
D0960 06 99.3 (3.7) R +++d
D1817 04 159.0 (3.4) R +++
D2282 06 172.5 (1.5) R +++d
Serum resistance phenotypes were determined using the Bioscreen growth
method. R, resistant (>80% growth in serum); S, sensitive (<20% growth in
serum); and I, intermediate (20–80% growth in serum) at 12 h. RAPD types are
strain types as determined previously by RAPD PCR and exopolysaccharide (EPS)
phenotypes were previously determined by growth on yeast extract mannitol
media (Mahenthiralingam et al., 1996; Zlosnik et al., 2008). Experiments were
performed in triplicate on three separate days. X=RAPD type not assigned but
does not match a major existing RAPD type.
across a time-span, it should be easy to validate this experimental
approach using other plate reader equipment as all that is required
is optical density measurements at 0 and 12 h,with shaking at 37˚C
in between.
The issue of serum resistance in BCC is important due to the
capacity of BCC to cause devastating and often quickly fatal necro-
tizing bacteremic pneumonia (Isles et al., 1984). To date there have
been several studies on serum resistance in BCC bacteria, that
have shown that clinical isolates from the pulmonary tract may
be serum resistant (Butler et al., 1994; Ortega et al., 2005; Savoia
et al., 2008). This is the ﬁrst study to examine serum resistance in
the context of strain background in B. cenocepacia, as determined
by the PCR based RAPD typing method (Mahenthiralingam et al.,
1996). The strain background of clinical isolates also did not seem
to be a determining factor in serum resistance as representative iso-
lates from the major epidemic clonal lineages (RAPD types 01, 02,
04, and 06) exhibited both serum sensitivity and serum resistance
(Tables 1 and 3). Applying this assay to clinical isolates allowed
us to observe that there is apparently no direct link between the
capacity of an isolate to elaborate exopolysaccharide, as previously
determined on yeast extract mannitol media, and its ability to
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resist the bactericidal effects of human serum in LB, however this
analysis must be caveated with the comment that the quantity of
EPS produced by BCC bacteria during growth in LB liquid culture
is not clear. Furthermore, this study is limited because it would
need to be powered with a very large number of isolates to pro-
vide statistically signiﬁcant proof that there is no link between
exopolysaccharide production and serum resistance and given the
small numbers of BCC infections, this is difﬁcult to achieve. Fur-
ther work is required to understand all the mechanisms involved
in serum resistance. It has been shown that possession of a full LPS
can confer serum resistance on BCC (Ortega et al., 2005), however
as isolate C8963 has a rough LPS phenotype and is serum resis-
tant (Table 1 and Conway et al., 2004) there may be alternative
mechanisms of resistance available to BCC bacteria, such as other
alterations to the outer membrane or the production of factors
that could inhibit the assembly of the MAC.
Using both methods, we have observed that the last stored pul-
monary isolate from BCC infected CF patients, who subsequently
died from cepacia syndrome, most often displayed either a serum
sensitive or serum intermediate phenotype (Table 1). However,
it is important to note that although this sample set contains
over 30 years of BCC cases across two clinics, the small num-
bers of cepacia syndrome cases makes a statistical link impossible.
Nonetheless we consider these observations from clinical isolates
to be valuable data because they suggest that in vitro assessment
of serum resistance cannot be used as a marker of subsequent ﬁt-
ness for bloodstream invasion. Speciﬁcally, the last isolate prior to
cepacia syndrome in seven out of the nine cases was assessed as
either serum sensitive (three cases) or serum intermediate (four
cases; Table 1). To explain the apparent contradiction that the last
stored isolate from patients that subsequently develop cepacia syn-
drome are most often not resistant to serum, there are a number of
possibilities that require further investigation. Firstly, BCC bacte-
ria are known for their phenotypic plasticity (Mahenthiralingam
et al., 2005); therefore it is conceivable that the bacteria acquire
serum resistance between the date of the last pulmonary isolate
and subsequent cepacia syndrome. Phenotypic variation is known
to be present within the individual sputum samples (Larsen et al.,
1993); therefore, another possibility is that a sub-population of
the sputum sample, not captured when these isolates were har-
vested and stored, is ultimately responsible for invasion. Indeed,
supportive of these previous observations, phenotypic variation
was observed from a sample from the same day in this study; with
two separate isolates from the same day for clinical case BCC5
being characterized as serum intermediate and resistant respec-
tively (Table 1). Finally, another limitation of the present study
is the use of pooled sera from non-CF donors. Regrettably sera,
blood isolates, and DNA from these patients is not available to
conduct a study into the competence of the sera from these indi-
viduals to kill the isolates of BCC that ultimately resulted in their
death.
In conclusion, we have developed a relatively high throughput
technique for assessing serum resistance in bacterial isolates. This
technique has proven robust in our hands and was effective at
screening larger numbers of isolates than the conventional assay
for serum resistance. We believe this is the largest survey to date
of serum resistance in clinical isolates of BCC bacteria and we
have shown that further work is required to understand how, at
least in some cases, patients who harbor serum sensitive isolates of
BCC can subsequently develop“cepacia syndrome”. The technique
described herein should be of considerable utility in assessing the
mechanisms by which BCC bacteria resist the inhibitory effects of
serum. Furthermore it could be easily adapted and applied for use
with other bacterial species, to determine whether they are capable
of resisting the complement components of human sera.
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